Millennium: The Takeda Oncology Company
United States
281 articles about Millennium: The Takeda Oncology Company
-
Millennium: The Takeda Oncology Company Submits Supplemental New Drug Application with FDA for Long-Term Overall Survival Results of VELCADE in Previously Untreated Multiple Myeloma
7/19/2011
-
Millennium: The Takeda Oncology Company Release: Data on MLN8237, an Investigational Aurora A Kinase Inhibitor, Presented at International Lymphoma Conference
6/23/2011
-
Millennium: The Takeda Oncology Company and Seattle Genetics, Inc. Present Clinical Data on ADCETRIS(TM) (Brentuximab Vedotin) in Systemic ALCL at European Hematology Association Annual Meeting
6/10/2011
-
Data Presentations Showcase Millennium: The Takeda Oncology Company Leadership in Protein Homeostasis at 16th Congress of the European Hematology Association
6/10/2011
-
Millennium: The Takeda Oncology Company Release: Novel VELCADE Based Combinations Show High Responses in Heavily Pre-Treated Patients with Relapsed or Refractory Multiple Myeloma
6/7/2011
-
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company Present Updated Brentuximab Vedotin (SGN-35) Data at American Society of Clinical Oncology Annual Meeting
6/6/2011
-
Millennium: The Takeda Oncology Company Highlights New Protein Homeostasis Data in Metastatic Melanoma and Other Solid Tumors at American Society of Clinical Oncology
6/6/2011
-
Takeda Pharmaceutical Co. Ltd.'s Deborah Dunsire Is Taking on Cancer; After Reinvigorating Millennium: The Takeda Oncology Company, Can She do the Same for Osaka-based Takeda?
3/18/2011
-
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company Announce Initiation of a Phase I Clinical Trial of Brentuximab Vedotin in Combination with Chemotherapy for Front-line Systemic ALCL
3/1/2011
-
Millennium: The Takeda Oncology Company CEO Deborah Dunsire Named MassBio Innovative Leadership Award Recipient
3/1/2011
-
Journal of Clinical Oncology Publishes Clinical Trial Results of Millennium: The Takeda Oncology Company's VELCADE Combination in Aggressive Subtypes of Non-Hodgkin Lymphoma
2/7/2011
-
Millennium: The Takeda Oncology Company Release: Fortune Magazine Names Millennium Among 100 Best Companies to Work for
1/20/2011
-
Onyx Pharmaceuticals, Inc. Drug Carfilzomib Reduces Cancer in a Third of Patients With Deadly Blood Cancer in Phase 2 Study; Raising Stakes in Rivalry with Millennium: The Takeda Oncology Company
12/8/2010
-
Millennium: The Takeda Oncology Company Release: Weekly VELCADE in Combination with Rituximab Improves Progression-Free Survival and Response Rate in Patients with Relapsed or Refractory Follicular Lymphoma
12/8/2010
-
Millennium: The Takeda Oncology Company Release: Subcutaneous Administration of Single-Agent VELCADE Demonstrates Efficacy Consistent with Intravenous Administration
12/8/2010
-
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company's Experimental Drug, SGN-35 Shrinks Hodgkin's Tumors, Study Shows
12/7/2010
-
Millennium: The Takeda Oncology Company Release: Oral Presentation Showcases Results of MLN4924 in Patients with Acute Myeloid Leukemia or High-Grade Myelodysplastic Syndromes
12/7/2010
-
Millennium: The Takeda Oncology Company Release: VELCADE(R) (bortezomib) Induction, Maintenance and Subcutaneous Data in Multiple Myeloma to Be Featured in Oral Presentations At American Society of Hematology Annual Meeting
11/10/2010
-
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company to Present Brentuximab Vedotin (SGN-35) Clinical Data at American Society of Hematology Annual Meeting
11/8/2010
-
Millennium: The Takeda Oncology Company and Takeda Pharmaceutical Co. Ltd. Announce Advancement of Prostate Cancer Program
11/4/2010